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Objective: To determine the prevalence of single and mixed dyslipidemias among patients 
treated with statins in clinical practice in France.
Methods: This is a prospective, observational, cross-sectional, pharmacoepidemiologic study 
with a total of 2544 consecutive patients treated with a statin for at least 6 months.
Main outcome measures: Prevalence of isolated and mixed dyslipidemias of low density 
lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides 
among all patients and among patients at high cardiovascular risk; clinical variables associated 
with attainment of lipid targets/normal levels in French national guidelines.
Results: At least one dyslipidemia was present in 50.8% of all patients and in 71.1% of high-risk 
patients. Dyslipidemias of LDL-C, HDL-C, and triglycerides were present in 27.7%, 12.4%, 
and 28.7% of all patients, respectively, and in 51.0%, 18.2%, and 32.5% of high-risk patients, 
respectively. Among all subjects with any dyslipidemia, 30.9% had mixed dyslipidemias and 
69.4% had low HDL-C and/or elevated triglycerides, while 30.6% had isolated elevated LDL-C; 
corresponding values for high-risk patients were 36.8%, 58.9%, and 41.1%. Age, gender, body 
mass index and Framingham Risk Score .20% were the factors significantly associated with 
attainment of normal levels for $2 lipid levels.
Conclusions: At least one dyslipidemia persisted in half of all patients and two-thirds of high 
cardiovascular risk patients treated with a statin. Dyslipidemias of HDL-C and/or triglycerides 
were as prevalent as elevated LDL-C among high cardiovascular risk patients.
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Introduction
Elevated low-density lipoprotein cholesterol (LDL-C) is the primary treatment 
target for patients at risk of coronary heart disease (CHD).1,2 Hence, European 
guidelines for reducing cardiovascular risk focus on lowering serum levels of 
LDL-C (and total cholesterol [TC]).2,3 However, low serum levels of high-density 
lipoprotein cholesterol (HDL-C) and elevated levels of triglycerides also increase 
the risk of CHD,4–9 even in patients treated with statins and with low LDL-C levels.9 
Serum levels of HDL-C and   triglycerides tend to be inversely correlated, likely reflect-
ing their   respective   participation in lipid transport and reverse cholesterol transport.10 
The inverse   relationship holds in the effects of lipid-modifying drugs – niacin,11 
fibrates,11statins,12,13 and cholesteryl ester transfer protein (CETP) inhibitors,14 all 
concomitantly increase HDL-C and decrease triglyceride levels – and in the effects 
of certain genetic mutations.15–21 This suggests that the separate   dyslipidemias of 
low HDL-C and elevated triglycerides may be viewed in combination.
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Previous studies of dyslipidemia in primary care in France 
have either focused on LDL-C and/or TC22–24 or have reported 
values for individual lipids (TC and triglycerides;25 LDL-C, 
HDL-C, and triglycerides26) according to NCEP ATP III 
guidelines.25,26 Studies of mixed dyslipidemias in European 
countries have applied NCEP ATP III guidelines27 or modified 
JES III guidelines.28 Studies set in primary care in France have 
reported rates of mixed dyslipidemias of LDL-C, HDL-C, 
and triglycerides according to European JES III guidelines, 
published in 2003.29,30 Bruckert et al reported rates of mixed 
dyslipidemias of HDL-C and triglycerides in 11 European 
countries, including France, according to JES III and NECEP 
ATP III guidelines.31
In France the Agence Française de Securite Sanitaire des 
Produits de Sante (AFSSAPS) has developed national guidelines 
for the management of dyslipidemia that differ in important ways 
from the European guideline.32 In particular, the thresholds for 
LDL-C for patients not categorized as high risk differ in the AFS-
SAPS and JES IV guidelines, and in AFSSAPS the threshold 
for HDL-C is the same for men and women (Table 1). Currently, 
the AFSSAPS are the most commonly used and recommended 
guidelines for patients treated with lipid-modifying therapy in 
France. Accordingly, prior studies assessing achievement of 
target LDL-C levels among statin-treated patients in France 
have applied the AFSSAPS definition.23,33,34 The objective of 
this paper is to further evaluate single and mixed dyslipidemias 
among patients treated with statins in clinical practice in France, 
applying the AFSSAPS guidelines.
Methods
Study design and data source
This was a prospective, observational, cross-sectional, pharma-
coepidemiologic study of patients receiving lipid-modifying 
therapies that included a statin. The data source was the 2006 
BKL-Thales database.22,33–38 Physicians in the Thales panel 
compose a nationally representative sample, based on crite-
ria of age, gender, and area of practice. They maintain their 
patients’ medical and prescription records using proprietary 
computer software and transmit coded extracts into the Thales 
database. To collect additional data for this study, a supple-
mentary questionnaire was added to the physicians’ software 
program. No intervention was made to affect the physicians’ 
prescribing behavior and the identities of neither the physicians 
nor patients were recorded in the data set analyzed.
Study sample
The source population consisted of consecutive patients who 
agreed to participate in the supplementary survey during a 
routine visit to a general practitioner belonging to the Thales 
network. Physicians recruited dyslipidemic patients who had 
been treated with a statin for at least 6 months and who had 
a complete lipid profile (LDL-C, HDL-C, and triglycerides) 
within the past 6 months. Patients were excluded from the 
study if their statin treatment had been modified (indicated 
by a change in International Nonproprietary Name [INN] or 
daily dosage) in the 3 months prior to the lipid panel or if 
they declined to participate.
The 2006 Thales database contains records of the lipid-
modifying drug treatment of approximately 150,000 patients 
by 1200 physicians. The sample size necessary to show that 
30% of patients had not attained their LDL-C target with an 
alpha of 0.05, a delta of 1.6%, and a power of 95% was cal-
culated to be 3151. The target sample size was thus 3000.
Data collection
Seven hundred general practitioners were randomly selected 
from the Thales panel and sent letters inviting them to 
Table 1   Comparison  of  French  (AFSSAPS)  and  European 
guidelines lipid thresholds for dyslipidemia
Lipid parameter French (AFSSAPS)33 European guideline   
(JES IV)2
LDL-C
  High risk*,† ,100 mg/dL ,100 mg/dL (option  
of ,80 mg/dL)
  Not high risk‡
  $ 3 risk factors ,130 mg/dL ,115mg/dL
    2 risk factors ,160 mg/dL ,115mg/dL
    1 risk factor ,190 mg/dL ,115mg/dL
    0 risk factors ,220 mg/dL ,115mg/dL
HDL-C
  Men ,40 mg/dL ,40 mg/dL
  Women ,40 mg/dL ,45 mg/dL
Triglycerides .150 mg/dL .150 mg/dL
Notes: *High cardiovascular risk was defined in the French guideline by a diagnosis of 
cardiovascular disease, a diagnosis of high-risk type 2 diabetes, and/or a 10-year CHD 
risk .20%.33 High-risk diabetes was defined as diabetes mellitus with concomitant 
renal disease and/or at least two of the following cardiovascular risk factors: age, 
family  history  of  coronary  disease,  HDL-C  ,40  mg/dL,  and  microalbuminuria 
(.30 mg/24 hours).33 †In the JES IV guideline, the following high-risk patient groups 
have priority in lipid treatment: (1) those with established CVD; (2) asymptomatic 
individuals with (a) multiple risk factors resulting in $5% risk of CV-related death in 
the next 10 years, (b) diabetes, or (c) markedly increased single risk factors; and (3) 
those with a family history of early CVD or high CV risk. Factors used to calculate risk 
are age, sex, smoking status, total cholesterol, and blood pressure. ‡Risk factors in the 
French guideline were age ($50 for men and $60 for women); tobacco use (currently 
smoking or stopped ,3 years earlier); a family history of early-onset coronary disease 
(MI or sudden death before age 55 in the father or first-degree male relative, and 
MI or sudden death before age 65 in the mother or first-degree female relative); 
permanent hypertension (diagnosis of hypertension ($140/90 mmHg) or treatment 
with antihypertensive agents); type 2 diabetes (treatment with anti-diabetic agent or 
diagnosis of diabetes); and HDL-C ,40 mg/dL regardless of gender.33
Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density 
lipoprotein cholesterol; CHD, coronary heart disease; CVD, cardiovascular disease; 
MI, myocardial infarction.
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  participate in the study. Three successive reminder letters 
were sent to physicians who did not respond. Patient data 
were collected prospectively via the computer network over a 
6-month period from December 2007 to May 2008. Data were 
collected from existing medical records in the Thales data-
base and via the computerized supplementary   questionnaire. 
Data collected from existing records included the date of 
consultation, patient age, gender, diagnoses of hypertension 
and diabetes (treated or not), diagnosis of dyslipidemia, 
and prescription of a lipid-modifying agent. Data collected 
from the supplementary questionnaire included the patient’s 
weight, height, blood pressure, family history of early onset 
cardiovascular event, and smoking status (current or regular 
smoker, or stopped within past 3 months). Certain conditions 
were identified from a combination of the Thales data set 
and the supplementary questionnaire: proven coronary heart 
disease (CHD), proven cardiovascular disease (CVD), renal 
impairment, proteinuria, and microalbuminuria.
Definitions
Permanent hypertension was defined in the Thales data set as 
140/90 mmHg (130/90 mmHg if diabetes present), measured 
as the mean of the last three values recorded. Proven CHD was 
defined in the Thales data set as a combination of a diagnosis of 
angina and three prescriptions per year of a nitrate derivative, 
beta-blocker, calcium channel inhibitor, or amiodarone. High 
cardiovascular risk was defined by a diagnosis of cardiovas-
cular disease, a diagnosis of high-risk type 2 diabetes, and/or 
a 10-year CHD risk .20% computed with the Framingham 
equation.39 High-risk diabetes was defined as diabetes mel-
litus with concomitant renal disease and/or at least two of the 
following cardiovascular risk factors: age, family history of 
coronary disease, HDL-C ,40 mg/dL, and microalbuminuria 
(.30 mg/24 hours). Cardiovascular risk factors were as defined 
by the AFSSAPS 2005 French national guideline (Table 1).32 
Obesity was defined as body mass index (BMI) $ 30 kg/m2 and 
abdominal obesity as a waist measurement .88 cm in women 
and .102 cm in men. Thresholds for dyslipidemia were as 
defined in the AFSSPAS guideline (Table 1).32
Data analysis
A descriptive analysis of patient characteristics and the 
prevalence of individual dyslipidemias (of LDL-C, HDL-C, 
or triglycerides) was carried out. Seven categories of mutu-
ally exclusive dyslipidemias were defined:29 isolated elevated 
LDL-C, isolated low HDL-C, isolated elevated triglycerides, 
elevated LDL-C and low HDL-C, elevated LDL-C and 
elevated triglycerides, low HDL-C and elevated triglycerides, 
and all three lipid abnormalities. Combinations of two or 
more dyslipidemias were called ‘mixed’. The proportions of 
all combinations of normal and abnormal lipid values were 
determined for the total study population and for high-risk 
patients. The distribution of dyslipidemias among subjects 
with dyslipidemia was also reported. Clinical factors asso-
ciated with attainment of AFSSAPS lipid threshold levels 
were assessed in multivariate regression models. The likeli-
hood of attaining target/normal levels for individual lipid 
parameters, ie, LDL-C, HDL-C, and triglycerides was com-
puted, adjusting for age (per 1 year increase), gender, BMI 
category, smoking status, hypertension, diabetes, history of 
cardiovascular disease, Framingham score risk .20%, and 
year of index prescription (2008 versus 2007). The same 
covariates were adjusted for in an analysis of attainment 
of two or more lipid target/normal levels (among LDL-C, 
HDL-C, and   triglycerides) versus attainment of LDL-C only. 
Analyses were performed using SAS software (v 9; SAS 
Institute, Cary, NC).
Results
Study population
Patient characteristics
Of 2707 patients treated with a statin, 2544 met the study 
inclusion–exclusion criteria (Figure 1). Of these, 1201 
2707 patients under
statin treatment
3 patients
demographically
ineligible
31 patients had <6
months of statin
treatment before
inclusion
129 changes of statin
therapy during the
past 3 months before
lipid measures
2544 patients
1201 high risk 1343 not high risk
Figure 1 Sample selection.
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(47.2%) were at high risk of cardiovascular events. The mean 
patient age was 65.8 years, 59.1% were men, and 71.7% 
had hypertension (Table 2). A history of cardiovascular 
disease was recorded for 31.8% of patients and 3.3% had a 
  Framingham risk score .20%.
Lipid-modifying drug therapies
Statin monotherapies were taken by 92.7% of the total patient 
sample (not tabulated). Statins were taken in combination 
with cholesterol absorption inhibitors by 4.8% and with other 
lipid-modifying therapies by 2.5% of patients. No patient 
received a statin in combination with a fibrate. Among the 
high-risk subgroup, 90.4% received statin monotherapies and 
statins were used in combination with cholesterol absorption 
inhibitors, omega-3 triglycerides, and other therapies by 
7.2%, 2.8%, and 1.8% of patients, respectively.
Prevalence of dyslipidemias
At least one dyslipidemia was present in 50.8% of all   subjects. 
As seen in Figure 2, the most prevalent dyslipidemias in the 
entire population were elevated triglycerides (28.7%) and 
elevated LDL-C (27.7%), while 12.4% had low HDL-C. 
Among all subjects with any dyslipidemia, 30.9% had mixed 
dyslipidemias (Table 3). Low HDL-C and/or elevated triglyc-
erides occurred in 69.4% of patients with any dyslipidemia, 
compared to 30.6% for isolated elevated LDL-C (Table 3).
At least one dyslipidemia was present in 71.1% of high-
risk subjects. Elevated LDL-C was the most prevalent dyslip-
idemia (51.0%), while dyslipidemias of elevated triglycerides 
and low HDL-C occurred in 32.5% and 18.2%, respectively, 
of high-risk patients (Figure 3). Among those at high risk with 
any dyslipidemia, 36.8% had mixed dyslipidemias (Table 3). 
Low HDL-C and/or elevated triglycerides occurred in 58.9% 
of high-risk patients with any dyslipidemias, compared to 
41.1% for isolated elevated LDL-C (Table 3).
All three dyslipidemias occurred in 4.6% of all patients 
and 6.3% of high-risk patients with any dyslipidemia 
(Table 3).
Variables associated with lipid goal 
attainment
A Framingham risk score .20% was the factor most strongly 
associated with attainment of lipid goal/normal level, with 
odds ratio (OR) values of 0.011, 0.210, and 0.564 for 
LDL-C, HDL-C, and triglycerides, respectively (P , 0.01 
for all effects; Table 4). A history of CVD/CHD was also 
associated with attainment of goals/normal level for all lipid 
parameters except triglycerides, for which the effect did not 
reach statistical significance.
Several variables were significantly associated with 
normal level attainment for HDL-C and/or triglycerides but 
not LDL-C goal, or vice versa. Older age was associated 
with greater odds of attaining normal level for HDL-C and 
triglycerides but not the LDL-C goal. Similarly, a diagnosis of 
diabetes and BMI categories of 25–30 kg/m2 and .30 kg/m2 
were associated with reduced odds of attaining normal 
  levels for HDL-C and triglycerides but not the LDL-C goal. 
  Conversely, being a current smoker reduced the odds of 
LDL-C goal attainment but not attainment of normal levels 
for HDL-C or triglycerides. Male gender increased the odds 
of attaining the LDL-C target but decreased the odds of 
attaining the normal level for HDL-C.
The odds of attaining goal/normal level for $2 lipid 
parameters followed the pattern for HDL-C and triglycerides 
for age, BMI categories, smoking status, Framingham risk 
Table 2 Patient characteristics
Characteristics All patients  
(N = 2544)
High risk  
(N = 1201)
Age, years (SD) 65.75 (10.79) 68.36 (9.79)
Male gender, n (%) 1503 (59.08) 885 (73.69)
Cardiovascular risk factors
  Current smoker, n (%) 273 (10.73) 138 (11.49)
  Hypertension, n (%) 1825 (71.74) 961 (80.02)
    Hypertension medication use, n (%) 1584 ( 62.26) 840 (69.94)
    Systolic BP $140 mmHg, n (%) 928 (36.48) 506 (42.13)
    Diastolic BP $90 mmHg, n (%) 184 (7.23) 93 (7.74)
  Family history of CHD, n (%) 392 (15.41) 193 (16.07)
Diabetes mellitus
  HBA1c,a mean (SD) 6.92 (1.16) 6.90 (1.18)
  FBG,b mean (SD) 1.36 (0.59) 1.36 (0.61)
  Diabetes medication use, n (%) 631 (24.80) 561 (46.71)
Body mass index (kg/m²), n (%)c
  25% or less 762 (30.23) 308 (25.90)
 . 25% and ,30% 1103 (43.75) 516 (43.40)
  30% or more (obesity) 656 (26.02) 365 (30.70)
  Abdominal obesity,d n (%) 763 (44.16) 398 (48.54)
Menopause, n (% of women) 190 (18.25)e 49 (15.51 )
Alcohol, n (%) 60 (2.36) 34 (2.83)
High cardiovascular riskf
  1. History of cardiovascular diseaseg n (%) 809 (31.80) 809 (67.36)
    Stroke, n (%) 440 (17.30) 440 (36.64)
    CHD, n (%) 573 (22.52) 573 (47.71)
  2. High-risk diabetes mellitus,h n (%) 514 (20.20) 514 (42.80)
  3. .20% 10-year risk, n (%) 83 (3.26) 83 ( 6.12)
  Any of criteria (1)–(3), n (%) 1201 (47.21) 1201(100)
Notes: All percentages referred to the overall sample in column 1 (2.544 patients) 
and to the overall number of high-risk patients in column 2, except for the following 
specific populations:  aN = 590 (all patients), N = 524 (high risk);  bN = 495 (all 
patients), N = 440 (high risk); cN = 2521 (all patients), N = 1189 (high risk); dN = 
1728 (all patients), N = 820 (high risk); e190 women out of 1041; 49 women out of 
316; fby French (AFSAPPS) criteria;33 gCHD or ischemic stroke; hhigh-risk diabetes: 
patients with diabetes mellitus and at least two other cardiovascular risk factors or 
diabetes with a concomitant renal disease.
Abbreviations: SD, standard deviation; BP, blood pressure; CHD, coronary heart 
disease; FBG, fasting blood glucose; HBA1c, glycosylated hemoglobin.
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lipid thresholds defined in JES III rather than in the AFSSAPS 
guideline.29 The principal difference between the two guide-
lines is that AFSSAPS has less stringent targets for LDL-C 
for patients not at high risk (Table 1). In addition, patients in 
the earlier study were selected for being prescribed either a 
statin or fibrate, so that 67.1% used statin monotherapy and 
31.8% used fibrate monotherapy. In the current study 92.7% 
of patients received statin monotherapy and none received 
fibrates. Possibly for these reasons, the proportions of patients 
with elevated LDL-C differed in the two studies: 73.2% in the 
previous study and 27.7% in the present study. The propor-
tions of patients with low HDL-C and elevated triglycerides 
were similar in the two studies but the relative contributions 
differed. Dyslipidemias of HDL-C and/or triglycerides were 
present in 46.3% of patients with any dyslipidemia in the 
previous study versus 69.4% in the present study. Results for 
the high-risk group in the current study more closely resem-
bled those in the previous study, possibly because the lipid 
thresholds for high-risk patients are nearly identical in the 
AFSSAPS and JES guidelines. Isolated LDL-C occurred in 
41.1% of high-risk patients with any dyslipidemia in the cur-
rent study versus 53.7% in the previous study.   Corresponding 
values for dyslipidemias of HDL-C and/ or triglycerides are 
58.9% and 46.3%, respectively.
Results show that prevalence rates of dyslipidemia in 
France, as observed in this study, are lower than those seen 
throughout Europe and Canada. Compared to results seen 
in the Dyslipidemia International Study (DYSIS) (an epide-
miologic multi-center, cross-sectional study of lipid profiles 
of 22,063 statin-treated outpatients in 11 European countries 
and Canada), French patients have a lower prevalence of 
low HDL-C (12.4% vs 26.3%), elevated LDL-C (27.7% vs 
48.2%), and elevated triglycerides (28.7% vs 38.2%).41
Low HDL-C (12.4%, n = 315)
 Elevated LDL-C (27.7%, n = 705)
 Elevated TG (28.7%, n = 731)
 15.1%
n = 384
4.5%
n = 114
3.5%
n = 89 2.4%
n = 60
2.0%
n = 52
15.6%
n = 395
7.8%
n = 198
No lipid disorder
49.2%, n = 1,252
Figure 2 Prevalence of dyslipidemias in all patients.*
Note: *N = 2,544 patients.
Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglycerides.
Table 3 Prevalence of dyslipidemias among all subjects and high-
risk subjects with at least one dyslipidemia
Dyslipidemia(s) All subjects  
(N = 1292)
High-risk 
subjects  
(N = 854)
N (%) N (%)
Individual dyslipidemia
  Elevated LDL-Ca 705 54.6% 613 71.2%
  Elevated triglyceridesa 731 56.6% 390 45.7%
  Low HDL-Ca 315 24.4% 219 25.6%
Isolated dyslipidemia
  Elevated LDL-C alone 395 30.6% 351 41.1%
  Elevated triglycerides alone 384 29.7% 120 14.1%
  Low HDL-C alone 114 8.8% 69 8.1%
Mixed dyslipidemiasb 399 30.9% 314 36.8%
  Two dyslipidemias 339 26.2% 260 30.5%
    Low HDL-C and/or elevated  
triglycerides
897 69.4% 503 58.9%
    Low HDL-C and/or elevated  
triglycerides and elevated LDL-C
310 24.0% 262 30.7%
All three dyslipidemias 60 4.6% 54 6.3%
Notes: aWithout regard to other lipid parameters; bcombinations of two or more 
dyslipidemias.
Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density 
lipoprotein cholesterol.
score, and history of cardiovascular disease. Year of index 
statin prescription had no statistically significant association 
with any lipid goal attainment.
Comment
The proportion of patients meeting AFSSAPS criteria for 
high cardiovascular risk in this study (47.2%) was similar 
to the 51.2% in a previous study of mixed dyslipidemias in 
patients treated with lipid-modifying drugs in French general 
practice.29 The present study differs, however, in methodol-
ogy and results for dyslipidemias. The previous study applied 
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Factors associated with lipid goal attainment have been 
reported in several cross-sectional studies of patients treated 
with lipid-modifying drugs in France.23,26,29 Dallongeville 
et al reported that increased waist circumference was associ-
ated with a reduced likelihood of achieving the triglyceride 
normal level of 150 mg/dL26 – equivalent to the relation-
ship between BMI and attainment of a normal triglyceride 
level observed in the present study. In the study reported by 
  Ferrieres et al, variables associated with a reduced likelihood 
of achieving the 2005 AFSSAPS target for LDL-C – smoking 
status, diabetes, hypertension, CHD, and increased risk of 
CVD – matched those in the present study (with the excep-
tion of diabetes).23 Applying JES III criteria, Van Ganse 
et al reported that each additional cardiovascular risk factor 
increased the occurrence of dyslipidemias of HDL-C and/or 
triglycerides (with normal LDL-C), the joint dyslipidemia of 
LDL-C and triglycerides (with normal HDL-C), and all three 
dyslipidemias.29 These results correspond to the finding in 
the current study that a Framingham risk score .20% was 
associated with a reduced likelihood of attaining targets/
normal levels for $2 lipids.
Except for Framingham risk score and history of CVD/
CHD, cardiovascular risk factors tended to be significantly 
associated either with attainment of normal levels for 
HDL-C and/or triglycerides but not LDL-C goal, or vice 
versa. This may be related to the fact that statins, which 
primarily affect LDL-C, were the only lipid-modifying 
drug used by 92.7% of patients, or it may be a reflection 
Table 4 Clinical factors associated with attainment of targets/normal levels for individual lipids and two or more lipids among the 
total population
Predictor variablea Odds ratio (95% CI) associated with attainment of lipid target/normal level
LDL-C  
(N = 2521)
HDL-C  
(N = 2521)
Triglycerides  
(N = 2521)
$2 lipids*  
(N = 1822)
Age (per 1 year increase) NS 1.04 (1.03–1.05)† 1.02 (1.01–1.03)† 1.05 (1.02–1.07)†
Gender (M/F) 1.56 (1.23–1.98)† 0.52 (0.38–0.70)† NS 0.58 (0.34–0.99)§
Body mass index (kg/m²)
25–30 versus #25 NS 0.59 (0.42–0.83)‡ 0.59 (0.46–0.74)† 0.50 (0.26–0.95)§
.30 versus #25 NS 0.47 (0.32–0.68)† 0.32 (0.25–0.42)† 0.35 (0.17–0.69)‡
Diabetes (yes/no) NS 0.74 (0.56–0.98)§ 0.76 (0.61–0.94)‡ NS
Current smoker (yes/no) 0.44 (0.31–0.61)† NS NS NS
Hypertension (yes/no) 0.72 (0.57–0.90)‡ NS 0.71 (0.58–0.86)† NS
History of CVD/CHD and FRS
FRS . 20% versus FRS # 20% 0.01 (0.01–0.02)† 0.21 (0.14–0.32)† 0.56 (0.39–0.81)‡ 0.09 (0.03–0.31)†
History of CVD/CHD versus FRS # 20% 0.12 (0.09–0.15)† 0.48 (0.36–0.64)† NS 0.39 (0.23–0.63)†
Notes:  aAll models included: age, gender, body mass index, diabetes status, smoking status, hypertension status, history of CVD/CHD, FRS (./,20%), year of statin 
prescription; *attainment of thresholds in $2 lipid parameters versus attainment of LDL-C target only; †P # 0.001; ‡P # 0.01; §P # 0.05.
Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CHD, coronary heart disease; CVD, cardiovascular disease; FRS, 
Framingham Risk Score.
Low HDL-C (18.2%, n = 219)
 Elevated LDL-C (51.0%, n = 613)
 Elevated TG (32.5%, n = 390)
 10.0%
n = 120
5.8%
n = 69
4.3%
n = 52 4.5%
n = 54
3.7%
n = 44
29.2%
n = 351
13.7%
n = 164
No lipid disorder
28.9%, n = 374
Figure 3 Prevalence of dyslipidemias in high-risk patients.*
Note: *N = 1201.
Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglycerides.
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of the structure of the AFSSAPS guideline, in which risk 
factors escalate the target for LDL-C but not the normal 
levels for other lipids. Current smoking and hypertension 
are risk factors that trigger a more stringent LDL-C target 
in the AFSSAPS guideline, and this may explain their asso-
ciation with a reduced likelihood of attaining the LDL-C 
goal. However, other risk factors – diabetes and age – were 
not significantly associated with LDL-C goal attainment. 
A relationship between male gender and a higher rate of 
LDL-C goal attainment has been reported previously.40–42 
The explanation for this is unclear, although it is possible 
that men either receive more aggressive treatment40 or are 
more adherent to statin regimens than are women.43,44 Not 
surprisingly, the pattern of risk factors associated with goal/
normal level attainment for mixed dyslipidemias (interpreted 
as $2 lipids versus LDL-C alone) tended to follow the 
pattern for HDL-C and triglycerides – specifically for age, 
BMI categories, smoking status, Framingham risk score, 
and history of cardiovascular disease. Unfortunately, the 
electronic database did not include reliable information on 
dietary behaviors and exercise, which can also impact goal/
normal lipid level attainment. Additional studies are needed 
to assess the differential impact of these factors, controlling 
for the abovementioned characteristics, on the prevalence of 
dyslipidemias despite lipid-modifying treatment.
Conclusion
By applying French national guidelines, we observed at 
least one dyslipidemia to be present among more than half 
(50.8%) of these primary care patients treated with statins. 
About one-third (30.9%) of patients with any dyslipidemia 
had mixed dyslipidemias, with low HDL-C and/or elevated 
triglycerides occurring in more than two-thirds (69.4%) 
of patients with any dyslipidemia, compared to 30.6% for 
isolated elevated LDL-C.
According to most guidelines, elevated LDL-C is one 
of, if not the primary, treatment target for reducing cardio-
vascular risk.1–3 The persistence of elevated LDL-C, even 
among patients already on lipid-modifying therapy, and 
particularly among patients at high cardiovascular risk, 
suggests that current statin treatment (with which .90% of 
patients in this sample were treated) is not adequate. In light 
of evidence showing that low HDL-C and elevated TGs are 
also associated with increased risk of CHD,4–9 along with 
our observations of the prevalence of mixed dyslipidemias 
both before and after lipid modifying therapies, suggests that 
patients may benefit from the addition of therapies targeting 
HDL-C and/or triglycerides.
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